title: Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers.
abstract: OBJECTIVE
  To evaluate patterns of recurrence for ovarian, fallopian tube, and primary peritoneal cancer patients undergoing extended treatment with bevacizumab (BEV).
  
  
  METHODS
  A retrospective review of patients with primary ovarian, fallopian tube, or peritoneal cancer treated with BEV alone or in combination with other chemotherapy from 2001 to 2011 was performed. Qualified patients were identified by chemotherapy records. Electronic medical records, labs, and imaging reports were reviewed and abstracted.
  
  
  RESULTS
  Of 108 patients identified, 89 patients met study criteria by having disease progression either during treatment with BEV or after discontinuing BEV without initiating any other treatment. Patients on extended BEV therapy (>12 cycles) were more likely to recur in extra-visceral sites (p=0.04), especially in lymph nodes (p=0.0002), and presented with fewer symptoms at time of recurrence (p=0.02), compared to patients who had received ≤ 12 cycles. CA-125 becomes less reliable for the detection of recurrent disease with extended BEV therapy (p=0.03 for ≤12 cycles vs. p=0.08 for >12 cycles). Radiology was superior to CA-125, symptom, and physical exam, in detecting recurrence with extended BEV therapy (all p<0.0001).
  
  
  CONCLUSIONS
  Extended treatment with BEV in ovarian, fallopian tube, and peritoneal cancers results in alterations in the patterns of recurrence. Radiologic imaging is more reliable than CA-125, symptoms, or physical exam, in identifying recurrent disease in patients undergoing BEV treatment. As novel targeted therapies continue to be employed, guidelines for gynecologic cancer surveillance must continue to be reexamined.
authors: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 98195-6460, USA.
authors: Minh D
authors: MD
authors: Dao
authors: Laura M
authors: LM
authors: Alwan
authors: Heidi J
authors: HJ
authors: Gray
authors: Hisham K
authors: HK
authors: Tamimi
authors: Barbara A
authors: BA
authors: Goff
authors: John B
authors: JB
authors: Liao
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D018394:CA-125 Antigen / Q000097:blood; D005185:Fallopian Tube Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D018394:CA-125 Antigen; D000068258:Bevacizumab
keywords: Bevacizumab; Ovarian cancer; Ovarian cancer surveillance; Ovarian cancer symptoms; Recurrence
references: J Clin Oncol. 2005 Dec 20;23(36):9338-43
references: 16361633
references: Cancer. 2011 Aug 15;117(16):3731-40
references: 21815133
references: Semin Oncol. 2003 Jun;30(3):401-12
references: 12870142
references: JAMA. 2004 Jun 9;291(22):2705-12
references: 15187051
references: Gynecol Oncol. 1991 Feb;40(2):103-6
references: 2010101
references: Gynecol Oncol. 2005 Nov;99(2):427-31
references: 16112718
references: Oncologist. 2007 Jan;12(1):72-8
references: 17227902
references: Lancet. 2010 Oct 2;376(9747):1155-63
references: 20888993
references: Ann Oncol. 2010 Nov;21(11):2201-2205
references: 20439341
references: Gynecol Oncol. 2012 Jan;124(1):59-62
references: 21982046
references: Gynecol Oncol. 2012 Mar;124(3):563-8
references: 22138229
references: J Clin Oncol. 2001 Oct 15;19(20):4054-7
references: 11600607
references: J Clin Oncol. 2003 May 15;21(10 Suppl):187s-193s
references: 12743133
references: Cancer. 1987 Oct 1;60(7):1561-6
references: 3621129
references: Br J Cancer. 2004 Jan 26;90(2):377-82
references: 14735180
references: Int J Gynecol Cancer. 2012 Jan;22(1):43-6
references: 22193642
references: N Engl J Med. 2011 Dec 29;365(26):2473-83
references: 22204724
references: N Engl J Med. 2011 Dec 29;365(26):2484-96
references: 22204725
references: Gynecol Oncol. 2006 Sep;102(3):425-8
references: 16797681
references: Eur J Radiol. 2009 Jul;71(1):164-74
references: 18378417
references: Ann Oncol. 1996 Apr;7(4):361-4
references: 8805927
references: Surg Gynecol Obstet. 1993 Apr;176(4):310-4
references: 8460404
references: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references: 10655437
references: J Clin Oncol. 2012 Jun 10;30(17):2039-45
references: 22529265
references: Crit Rev Oncol Hematol. 2009 Jul;71(1):43-52
references: 19179092
references: Int J Gynecol Cancer. 2007 Jan-Feb;17(1):21-31
references: 17291227
references: Am J Obstet Gynecol. 2011 Jun;204(6):466-78
references: 21752752
references: Int J Gynecol Cancer. 2005 Sep-Oct;15(5):824-9
references: 16174231
references: Cancer. 2008 Apr 15;112(8):1726-32
references: 18300236